Optimism for patients with genotype 4 HCV infection: Clinical trials with direct-acting antivirals finally available

Journal of Hepatology

Volumn 62, Issue 5, 2015, Pages 996-999

  Asselah, Tarik ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; BECLABUVIR; DACLATASVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ALPHA INTERFERON; BENZAZEPINE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; MACROGOL DERIVATIVE; SULFONAMIDE;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GENOTYPE; HEALTH CARE NEED; HEPATITIS C; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RELAPSE; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; CHRONIC HEPATITIS C; FEMALE; HEPACIVIRUS; MALE;

BENZAZEPINES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INDOLES; INTERFERON-ALPHA; ISOQUINOLINES; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SULFONAMIDES;

EID: 84927799911     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.03.003     Document Type: Editorial

References (18)

1. P.J. Ruane, D. Ain, R. Stryker, R. Meshrekey, M. Soliman, and P.R. Wolfe Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry J Hepatol 62 2015 1040 1046
2. C. Moreno, C. Hezode, P. Marcellin, S. Bourgeois, S. Francque, and D. Samuel Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4 J Hepatol 62 2015 1047 1055
3. T. Hassanein, K.D. Sims, M. Bennett, N. Gitlin, E. Lawitz, and T. Nguyen A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis c virus genotype 4 infection J Hepatol 62 2015 1204 1206
4. T. Asselah, P.V. Perumalswami, and D. Dieterich Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity Liver Int 34 2014 1447 1451
5. C. Frank, M.K. Mohamed, G.T. Strickland, D. Lavanchy, R.R. Arthur, and L.S. Magder The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt Lancet 355 2000 887 891
6. T. Asselah, S. De Muynck, P. Broët, J. Masliah-Planchon, M. Blanluet, and I. Bièche IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C J Hepatol 56 2012 527 532
7. E. Estrabaud, M. Vidaud, P. Marcellin, and T. Asselah Genomics and HCV infection: progression of fibrosis and treatment response J Hepatol 57 2012 1110 1125
8. T. Asselah, and P. Marcellin Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection Liver Int 35 2015 56 64
9. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
10. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2014; in press.
11. G.E. Esmat, G. Shiha, and R.F. Omar Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV infection Hepatology 60 662A 2014 63A [abstract]
12. R. Kapoor, A. Kohli, and S. Sidharthan All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial Hepatology 60 2014 321A [abstract]
13. Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. A Randomized, open-label study of ombitasvir and ABT-450/r with or without ribavirin in treatment-naïve and treatment-experienced patients with chronic hepatitis C virus infection (PEARL-I): Results in patients with genotype 4 infection. Lancet 2015, in press.
14. G.T. Everson, T.T. Tran, and W.J. Towner Safety and efficacy of treatment with interferon-free, ribavirin-free combination of sofosbuvir + GS-5816 for 12 weeks in treatment-naïve patients with genotypes 1-6 HCV infection J Hepatol 60 2014 S46 [Abstract O111]
15. European Association for Study of Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 60 2014 392 420
16. Abergel A, Loustaud-Ratti V, Metivier S, Jiang D, Kersey K, Knox SJ, et al. Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. EASL; 2015.
17. Asselah T, Hassanein T, Qaqish RB, Feld J, Hezode C, Zeuzem S, et al. A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis. EASL; 2015, P1345.
18. Asselah T, Charlton M, Feld J, Foster G, McNally J, Brainard DM, et al. The ASTRAL studies: Evaluation of SOF/GS-5816 Single Tablet Regimen for the Treatment of Genotype 1-6 HCV Infection. EASL; 2015, P1332.